Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

02-11-2022 | Alzheimer's Disease | Letter to the Editor

Positive opinion of the French National Authority for Health on the reimbursement of amyloid tracer (Flutemetamol)

Authors: Antoine Garnier-Crussard, Anthime Flaus

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2023

Excerpt

Dear Sir, …

French National Authority for Health - Haute Autorité de santé (HAS). Flutemetamol (VIZAMYL) - Transparency Committee [Internet]. 2022. Available from: https://www.has-sante.fr/upload/docs/evamed/CT-19717_VIZAMYL_PIC_INS_Avisdef_CT19717.pdf. Accessed 25 Aug 2022.

Fantoni ER, Chalkidou A, O’Brien JT, Farrar G, Hammers A. A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer’s Disease. J Alzheimers Dis. 2018;63:783–96.CrossRef

Landau SM, Horng A, Fero A, Jagust WJ. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology. 2016;86:1377–85.CrossRef

French National Authority for Health - Haute Autorité de santé (HAS). Florbetapir (AMYVID) - Transparency Committee [Internet]. 2013. Available from: https://www.has-sante.fr/upload/docs/evamed/CT-12957_AMYVID_PIC_INS_Avis3_CT12957.pdf. Accessed 25 Aug 2022.

French National Authority for Health - Haute Autorité de santé (HAS). Florbetaben (NEURACEQ) - Transparency Committee [Internet]. 2019. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2019-01/neuraceq_pic_ins_avis3_ct16710.pdf. Accessed 25 Aug 2022.

French National Authority for Health - Haute Autorité de santé (HAS) (2017) Flutemetamol (VIZAMYL) - Transparency Committee.

Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286.CrossRef

Altomare D, Collij L, Caprioglio C, Scheltens P, van Berckel BNM, Alves IL, et al. Description of a European memory clinic cohort undergoing amyloid-PET: the AMYPAD Diagnostic and Patient Management Study. Alzheimers Dement [Internet]. 2022. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/alz.12696. Accessed 25 Aug 2022.

NCT04426539. New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study - A Study to Improve Precision in Amyloid PET Coverage and Patient Care [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT04426539. Accessed 25 Aug 2022.

10.

Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7:e12179.

Title: Positive opinion of the French National Authority for Health on the reimbursement of amyloid tracer (Flutemetamol)
Authors: Antoine Garnier-Crussard
Anthime Flaus
Publication date: 02-11-2022
Publisher: Springer Berlin Heidelberg
Keywords: Alzheimer's Disease
Positron Emission Tomography
Alzheimer's Disease
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-06025-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Positive opinion of the French National Authority for Health on the reimbursement of amyloid tracer (Flutemetamol)

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2023

Polar map-free 3D deep learning algorithm to predict obstructive coronary artery disease with myocardial perfusion CZT-SPECT

Cancer photodynamic therapy with chlorin e6-loaded, goat milk-derived extracellular vesicles: [18F]FDG lights up the way

Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial

Enhanced antitumor immune responses via a new agent [131I]-labeled dual-target immunosuppressant

The role of radiographers in nuclear medicine; the link between patient and technology

Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy